This article explores the critical role of 5' RNA cap structures, specifically Cap1 and Cap2, in preventing unwanted innate immune activation—a central challenge in mRNA therapeutics and vaccine development.
The success of mRNA-based therapeutics, from vaccines to protein replacement therapies, is often challenged by the host's innate immune response, particularly the type I interferon (IFN) reaction triggered by exogenous...
The efficient escape of mRNA-loaded lipid nanoparticles (LNPs) from endosomal compartments is a pivotal yet inefficient step, with less than 2-5% of cargo typically reaching the cytosol.
This article provides a comprehensive analysis for researchers and drug development professionals on the critical role of pseudouridine (Ψ) and its derivatives in mitigating the immunogenicity of in vitro transcribed...
This article provides a comprehensive guide for researchers and drug development professionals on optimizing the 5' cap and poly(A) tail to enhance the stability, translational efficiency, and overall efficacy of...
This article provides a comprehensive overview of CleanCap co-transcriptional capping technology, a transformative approach for mRNA synthesis.
This article explores the transformative potential of modified mRNA (modRNA) technology in direct lineage conversion, a process that directly reprograms one specialized cell type into another without reverting to a...
This article provides a comprehensive analysis of Tissue Nanotransfection (TNT), a novel non-viral nanotechnology for in vivo mRNA delivery.
This article provides a comprehensive analysis for researchers and drug development professionals on the critical role of nucleoside modifications in mitigating the immunogenicity of mRNA-based therapeutics.
This article provides a comprehensive guide for researchers and drug development professionals on implementing a daily mRNA transfection protocol for cell reprogramming, such as the generation of induced pluripotent stem...